Advertisement Medarex and Compugen in antibody development deal - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Medarex and Compugen in antibody development deal

Medarex and Compugen have entered into a collaborative agreement to develop novel monoclonal antibody-based therapeutics for oncology and autoimmune diseases.

Under the terms of the agreement, Medarex and Compugen plan to share discovery, development and commercialization responsibilities on antibody-based therapeutics resulting from this collaboration, and share revenues generated from the sale of such therapeutic products.

Compugen expects to utilize its proprietary antibody-target discovery engine to identify novel drug targets. Medarex plans to develop fully human antibodies against these targets using its UltiMAb Human Antibody Development System. The collaboration also provides that Compugen may independently pursue diagnostic applications involving certain antibodies and targets.

Medarex said the new partnership offered it the opportunity to broaden the number of product candidates to treat cancer and autoimmune diseases in its current pipeline.